BOULDER - Clovis Oncology Inc. has tested its first U.S. patient in its TIGER2 cancer study, the company announced this week.

Boulder-based Clovis (Nasdaq: CLVS)  is in the process of testing CO-1686, an oral targeted inhibitor of mutant forms of an epidermal growth-factor receptor for the treatment of non-small-cell lung cancer, according to the company. The testing is referred to as TIGER2.

"The CO-1686 data observed to date have been highly consistent, including the growing evidence of a lengthy duration of benefit and the tolerability profile of the drug," said Patrick J. Mahaffy, president and CEO of Clovis, in a statement.

The company plans on filing a new drug application by mid-2015, after several more months of testing.

Testing of CO-1686 first occurred in Japan in the first quarter.